Martin Schlesinger

2.0k total citations · 1 hit paper
40 papers, 1.4k citations indexed

About

Martin Schlesinger is a scholar working on Oncology, Molecular Biology and Immunology and Allergy. According to data from OpenAlex, Martin Schlesinger has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 14 papers in Immunology and Allergy. Recurrent topics in Martin Schlesinger's work include Cell Adhesion Molecules Research (14 papers), Proteoglycans and glycosaminoglycans research (12 papers) and Platelet Disorders and Treatments (11 papers). Martin Schlesinger is often cited by papers focused on Cell Adhesion Molecules Research (14 papers), Proteoglycans and glycosaminoglycans research (12 papers) and Platelet Disorders and Treatments (11 papers). Martin Schlesinger collaborates with scholars based in Germany, Switzerland and Italy. Martin Schlesinger's co-authors include Gerd Bendas, Ulrich Massing, Lubor Borsig, Annamaria Naggi, Peter Jantscheff, T Ross, Giangiacomo Torri, Patrick W. Schmitz, Marko Roblek and Maurice Wilde and has published in prestigious journals such as PLoS ONE, ACS Applied Materials & Interfaces and International Journal of Molecular Sciences.

In The Last Decade

Martin Schlesinger

39 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of platelets and platelet receptors in cancer metastasis

2018 469 citations Martin Schlesinger profile →

Peers

Countries citing papers authored by Martin Schlesinger

Since Specialization

Citations

This map shows the geographic impact of Martin Schlesinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Schlesinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Schlesinger more than expected).

Fields of papers citing papers by Martin Schlesinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Schlesinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Schlesinger. The network helps show where Martin Schlesinger may publish in the future.

Co-authorship network of co-authors of Martin Schlesinger

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Schlesinger. A scholar is included among the top collaborators of Martin Schlesinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Schlesinger. Martin Schlesinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L 2024 ·Seminars in Thrombosis and Hemostasis ·Gerd Bendas, Martina Gobec, Martin Schlesinger	1
2	Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling 2023 ·International Journal of Molecular Sciences ·(unknown), Heiko B. Weber, (unknown), Martin Schlesinger, Christian Gorzelanny, Gerd Bendas	3
3	The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis 2022 ·Experimental Hematology and Oncology ·Gerd Bendas, Martin Schlesinger	24
4	Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin 2022 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), Vito Ferro, Gerd Bendas, Martin Schlesinger	13
5	Insulin-like Growth Factor Binding Protein-2 (IGFBP2) Is a Key Molecule in the MACC1-Mediated Platelet Communication and Metastasis of Colorectal Cancer Cells 2021 ·International Journal of Molecular Sciences ·(unknown), Dennis Kobelt, (unknown), Martin Schlesinger, Ulrike Stein, Gerd Bendas	11
6	Another structural correction for 1‐oxo‐1H‐phenalene‐2,3‐dicarbonitriles: Synthesis of a potent BCL‐2 inhibiting 7‐phenoxy derivative 2021 ·Archiv der Pharmazie ·Izidor Sosič, Martina Gobec, Christian Steinebach, Martin Schlesinger, Gerd Bendas, Michael Gütschow	0
7	β1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters 2020 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Martin Schlesinger, Gerd Bendas	65
8	Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways—Do They Share a Common Ground in Melanoma Cells? 2018 ·Thrombosis and Haemostasis ·(unknown), Manuel Grundmann, Tobias Benkel, (unknown), (unknown), Evi Kostenis, Martin Schlesinger, Neta Ilan, Israël Vlodavsky, Gerd Bendas	5
9	The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation 2018 ·PLoS ONE ·(unknown), (unknown), (unknown), Jens Müller, Bernd Pötzsch, Gerd Bendas, Martin Schlesinger	16
10	A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies 2016 ·Journal of Nanobiotechnology ·Savita Bisht, Martin Schlesinger, Alexander Rupp, Rolf Schubert, Jens Nolting, Joerg Wenzel, Stefan Holdenrieder, Peter Brossart, Gerd Bendas, Georg Feldmann	43
11	Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis 2015 ·Cancer and Metastasis Reviews ·Martin Schlesinger, Gerd Bendas	60
12	Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis 2015 ·Journal of Controlled Release ·Marko Roblek, Manuela Călin, Martin Schlesinger, Daniela Stan, Reiner Zeisig, Maya Simionescu, Gerd Bendas, Lubor Borsig	24
13	Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases 2015 ·Lipids in Health and Disease ·(unknown), Peter Jantscheff, T Ross, Martin Schlesinger, Maurice Wilde, (unknown), (unknown), Gerd Bendas, Ulrich Massing	60
14	VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes 2014 ·European Journal of Pharmaceutics and Biopharmaceutics ·Manuela Călin, Daniela Stan, Martin Schlesinger, Viorel Simion, Mariana Deleanu, Cristina Ana Constantinescu, Ana‐Maria Gan, (unknown), Elena Butoi, Ileana Mânduțeanu, (unknown), Marius Enăchescu, Lubor Borsig, Gerd Bendas, Maya Simionescu	43
15	The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin 2014 ·Thrombosis Research ·Martin Schlesinger, Marko Roblek, (unknown), Annamaria Naggi, Giangiacomo Torri, Lubor Borsig, Gerd Bendas	32
16	Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo 2011 ·Molecular Cancer Therapeutics ·Peter Jantscheff, Martin Schlesinger, (unknown), Lenka A. Taylor, Ralph Graeser, Gregor Kirfel, Dieter O. Fürst, Ulrich Massing, Gerd Bendas	44
17	Analysis of SM4 sulfatide as a P-selectin ligand using model membranes 2010 ·Biophysical Chemistry ·(unknown), Martin Schlesinger, (unknown), Lubor Borsig, Gerd Bendas	17
18	Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins 2010 ·International Journal of Clinical Pharmacology and Therapeutics ·Martin Schlesinger, Annamaria Naggi, Giangiacomo Torri, Reiner Zeisig, M. Yvonne Alexander, Patrick W. Schmitz, Benito Casu, Gerd Bendas	6
19	Reduction in human melanoma cell adhesion receptor activity by lysophosphatidylcholine (LPC) treatment – functional characterization and signal pathway analyses 2010 ·International Journal of Clinical Pharmacology and Therapeutics ·M. Yvonne Alexander, Martin Schlesinger, Peter Jantscheff, Ulrich Massing, Gerd Bendas	1
20	Binding between heparin and the integrin VLA-4 2009 ·Thrombosis and Haemostasis ·Martin Schlesinger, (unknown), Patrick W. Schmitz, (unknown), Gerd Bendas	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact